Aggressive R&D Initiatives and Innovative Pipelines - Research Report on J&J, Merck, AbbVie, Novartis, and GSK

Aggressive R&D Initiatives and Innovative Pipelines - Research Report on J&J,
                       Merck, AbbVie, Novartis, and GSK

PR Newswire

NEW YORK, March 7, 2013

NEW YORK, March 7, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE:
ABBV), Novartis AG (NYSE: NVS), and GlaxoSmithKline Plc (NYSE: GSK). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

Since the beginning of 2013, J&J has already surged 8.3 percent, primarily due
to its omnipresence in almost every corner of the health care industry, from
pharmaceuticals to medical supplies to personal care products and more. The
company's diversity and solid cash flow allows it to withstand pressures. In
February, a J&J pharmaceutical company, Janssen Pharmaceutical K.K., announced
its submission of a regulatory application to Japanese health authorities
seeking approval for simeprevir, administered with pegylated interferon and
ribavirin for the treatment of genotype 1 chronic hepatitis C patients. The
hepatitis C virus is rampant in Japan, affecting approximately 1.5 to two
million people. Furthermore on the pharmaceuticals segment, J&J's prostate
cancer drug Zytiga continues to beat expectations, recording over 300 percent
sales growth in the previous year, to $961 million. By 2015 the product is
expected to reach $1.8 billion. The Full Research Report on Johnson & Johnson
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/aab0_JNJ]

--

Merck & Co., Inc. Research Report

Looking to expand its biologics portfolio, Merck, in agreement with Samsung
Bioepis, plans to develop and commercialize multiple pre-specified and
undisclosed biosimilar candidates. Through Merck's global commercial presence,
combined with Samsung Bioepis' biologic development and manufacturing
capabilities, both companies are well positioned to increase access to
biosimilars to improve human health. Under the contract, Samsung Bioepis
covers the preclinical and clinical development, process development and
manufacturing, clinical trials, and registration; and Merck covers the
commercialization. The Full Research Report on Merck & Co., Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d004_MRK]

--

AbbVie Inc. Research Report

Relatively new in the industry, AbbVie was formed in 2013, following
emancipation from Abbott Laboratories. On March 1 the company was up 2.41
percent and closed at $37.81. Two years ago, the company was involved in the
first well-documented case of an infant who is functionally cured of HIV
infection. A drug manufactured by AbbVie was among the treatments prescribed
to the Mississippi patient. When the company spun off in January, it also
inherited the patents for the co-formulation, which it now markets as Kaletra.
According to experts, the treatment is a promising lead for additional R&D
toward curing other children. In 2016, patent protection of Kaletra is set to
expire. For this year, AbbVie expects to initiate several Phase IIB and Phase
III programs. The Full Research Report on AbbVie Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/2342_ABBV]

--

Novartis AG Research Report

The European Commission has recently approved Ilaris in the treatment of
patients with acute gouty arthritis who suffer frequent attacks, and whose
symptoms cannot or should not be managed with existing treatment options.
Ilaris is the only approved fully human monoclonal antibody targeting IL-1
beta, and is now being investigated in a number of rare inflammatory
conditions. Novartis also is taking initiatives to eliminate rheumatic heart
disease (RHD) in Zambia, Africa by treating children with streptococcal
infections and silent RHD by providing monthly penicillin injections. In
February, the company received multiple recognitions for having the most
innovative pipeline. The Full Research Report on Novartis AG - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/9659_NVS]

--

GlaxoSmithKline Plc Research Report

ViiV Healthcare, a global specialist HIV company established by GSK and
Pfizer, announced a collaboration with the Medicines Patent Pool (MPP),
granting MPP a voluntary license for pediatric formulations of the
antiretroviral medicine abacavir. To date, ViiV Healthcare has 13 voluntary
license agreements with generics companies that facilitate the manufacture and
sale of low-cost versions of its medicines. In line with the company's
commitment to make its pipeline available through royalty-free voluntary
licensing and not-for-profit initiatives, its pipeline products for HIV
treatment would be eligible to be licensed to MPP, upon approval of regulatory
agencies. The Full Research Report on GlaxoSmithKline Plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/1372_GSK]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers

press@investors-alliance.com

+1-480-745-7826

SOURCE Investors-Alliance